Top

Published in:

Open Access 01-03-2012

Current and novel renal biomarkers in heart failure

Authors: Kevin Damman, Adriaan A. Voors, Gerjan Navis, Dirk J. van Veldhuisen, Hans L. Hillege

Published in: Heart Failure Reviews | Issue 2/2012

Abstract

Renal function is the most important predictor of clinical outcome in heart failure (HF). It is therefore essential to have accurate and reliable measurement of renal function and early specific markers of renal impairment in patients with HF. Several renal functional entities exist, including glomerular filtration (GFR), glomerular permeability, tubulointerstitial damage, and endocrine function. Different markers have been studied that can be used to determine changes and the effect of treatment in these entities. In the present review, we summarize current and novel markers that give an assessment of renal function and prognosis in the setting of acute and chronic HF.

Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ (2009) Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the coordinating study evaluating outcome of advising and counseling in heart failure (COACH). Eur J Heart Fail 11:847–854PubMedCrossRef

Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210PubMed

Vaz Perez A, Otawa K, Zimmermann AV, Stockburger M, Muller-Werdan U, Werdan K, Schmidt HB, Ince H, Rauchhaus M (2010) The impact of impaired renal function on mortality in patients with acutely decompensated chronic heart failure. Eur J Heart Fail 12:122–128PubMedCrossRef

Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL (2007) Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13:599–608PubMedCrossRef

Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L (2008) Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 10:188–195PubMedCrossRef

Hata N, Yokoyama S, Shinada T, Kobayashi N, Shirakabe A, Tomita K, Kitamura M, Kurihara O, Takahashi Y (2010) Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 12:32–37PubMedCrossRef

Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31:703–711PubMedCrossRef

Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114:1572–1580PubMedCrossRef

Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S (2007) The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13:609–617PubMedCrossRef

10.

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van LF (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMed

11.

Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM (2005) Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 111:1270–1277PubMedCrossRef

12.

Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 94:957–960PubMedCrossRef

13.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed

14.

Miller BF, Winkler AW (1938) The renal excretion of endogenous creatinine in man. Comparison with exogenous creatinine and inulin. J Clin Invest 17:31–40PubMedCrossRef

15.

Ix JH, Wassel CL, Stevens L, Beck GJ, Froissart M, Navis GJ, Rodby R, Schmid CH, Torres V, Zhang Y, Greene T, Levey AS (2011) Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. CJASN 6:184–191PubMed

16.

Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681–689PubMedCrossRef

17.

Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47:1987–1996PubMedCrossRef

18.

Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, Steffes MW, Eggers PW, Coresh J, Levey AS (2010) Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 56:486–495PubMedCrossRef

19.

Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466–473PubMedCrossRef

20.

Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, Goudreau E, Cowley MJ, Vetrovec GW (2008) Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 101:1643–1647PubMedCrossRef

21.

Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, O’connor C, Adams KF, Orlandi C, Gheorghiade M (2007) Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) study. J Card Fail 13:360–364PubMedCrossRef

22.

Lin HJ, Chao CL, Chien KL, Ho YL, Lee CM, Lin YH, Wu YW, Hsu RB, Chou NK, Wang SS, Chen CY, Chen MF (2009) Elevated blood urea nitrogen-to-creatinine ratio increased the risk of hospitalization and all-cause death in patients with chronic heart failure. Clin Res Cardiol 98:487–492PubMedCrossRef

23.

Gotsman I, Zwas D, Planer D, Admon D, Lotan C, Keren A (2010) The significance of serum urea and renal function in patients with heart failure. Medicine (Baltimore) 89:197–203CrossRef

24.

Heywood JT, Elatre W, Pai RG, Fabbri S, Huiskes B (2005) Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 10:173–180PubMedCrossRef

25.

Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290:2581–2587PubMedCrossRef

26.

Shenkman HJ, Zareba W, Bisognano JD (2007) Comparison of prognostic significance of amino-terminal pro-brain natriuretic peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure. Am J Cardiol 99:1143–1145PubMedCrossRef

27.

Klein L, Massie BM, Leimberger JD, O’Connor CM, Pina IL, Adams KF Jr, Califf RM, Gheorghiade M (2008) Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail 1:25–33PubMedCrossRef

28.

Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1:2–5PubMedCrossRef

29.

Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699–707PubMed

30.

Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226PubMedCrossRef

31.

de Boer I, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, Rifkin DE, Sarnak MJ, Shlipak MG, Siscovick DS (2009) Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 32:1833–1838PubMedCrossRef

32.

Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef

33.

Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, Siscovick D, Psaty BM, Sarnak MJ (2005) Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45:268–271PubMedCrossRef

34.

Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, Fukui A, Tachibana H, Nozaki N, Hirono O, Tsunoda Y, Miyashita T, Shishido T, Takahashi H, Koyama Y, Kubota I (2005) Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail 11:595–601PubMedCrossRef

35.

Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28:1841–1847PubMedCrossRef

36.

Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18:2024–2031PubMedCrossRef

37.

Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW (1998) Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem 44:1535–1539PubMed

38.

Tidman M, Sjostrom P, Jones I (2008) A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant 23:154–160PubMedCrossRef

39.

Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP (1995) Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47:312–318PubMedCrossRef

40.

Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, Yamane S, Pei Z, Kojima S, Hamano Y, Mashiba S, Kurata M, Miyoshi KI, Higaki J (2010) Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol 14:584–588PubMedCrossRef

41.

Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the heart and soul study. Nephrol Dial Transplant 22:1087–1092PubMedCrossRef

42.

Filler G, Bokenkamp A, Hofmann W, Le BT, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR—history, indications, and future research. Clin Biochem 38:1–8PubMedCrossRef

43.

Agewall S, Wikstrand J, Ljungman S, Fagerberg B (1997) Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk factor intervention study group. Am J Cardiol 80:164–169PubMedCrossRef

44.

Brantsma AH, Bakker SJ, Hillege HL, de ZD, de Jong PE, Gansevoort RT (2008) Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 23:3851–3858PubMedCrossRef

45.

Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMedCrossRef

46.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927PubMedCrossRef

47.

Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM (2008) Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 295:F1589–F1600PubMedCrossRef

48.

Damman K, Hillege HL, van Veldhuisen DJ (2009) Albuminuria in heart failure: a CHARMing new risk factor? Lancet 374:506–508PubMedCrossRef

49.

Smilde TD, Damman K, van der HP, Navis G, Westenbrink BD, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clin Res Cardiol 98:121–129PubMedCrossRef

50.

Wegria R, Capeci NE, Blumenthal MR, Kornfeld P, Hays DR, Elias RA, Hilton JG (1955) The pathogenesis of proteinuria in the acutely congested kidney. J Clin Invest 34:737–743PubMedCrossRef

51.

Damman K, Navis G, Smilde TD, Voors AA, van der BW, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9:872–878PubMedCrossRef

52.

Damman K, van DV, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53:582–588PubMedCrossRef

53.

Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, Dargie HJ (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12:974–982PubMedCrossRef

54.

van de Wal RM, Asselbergs FW, Plokker HW, Smilde TD, Lok D, van Veldhuisen DJ, van Gilst WH, Voors AA (2005) High prevalence of microalbuminuria in chronic heart failure patients. J Card Fail 11:602–606PubMedCrossRef

55.

Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550PubMedCrossRef

56.

Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, Frisinghelli A, Minneci C, Valisi M, Maggioni AP, Marchioli R, Tognoni G, Tavazzi L (2010) Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-heart failure trial. Circ Heart Fail 3:65–72PubMedCrossRef

57.

Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRef

58.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN (2009) Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 120:1577–1584PubMedCrossRef

59.

Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D’Amico G (2002) Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 17:1890–1896PubMedCrossRef

60.

Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Jaber BL (2007) Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 18:904–912PubMedCrossRef

61.

Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NF (1975) Urinary N-acetyl-beta-d-glucosaminidase activities in patients with renal disease. Br Med J 3:408–411PubMedCrossRef

62.

Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ (2003) Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 18:543–551PubMedCrossRef

63.

Damman K, van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2010) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96:1297–1302PubMedCrossRef

64.

Mohkam M, Karimi A, Habibian S, Sharifian M (2008) Urinary N-acetyl-beta-d-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. Iran J Kidney Dis 2:24–28PubMed

65.

Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237–244PubMedCrossRef

66.

Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290:F517–F529PubMedCrossRef

67.

van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA (2007) Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212:209–217PubMedCrossRef

68.

Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV (2008) Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 73:863–869PubMedCrossRef

69.

Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G (2009) Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 53:16–25PubMedCrossRef

70.

Kramer AB, van Timmeren MM, Schuurs TA, Vaidya VS, Bonventre JV, van GH, Navis G (2009) Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal kidney injury molecule (Kim-1) over time. Am J Physiol Renal Physiol 296:F1136–F1145PubMedCrossRef

71.

Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J (2007) Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18:407–413PubMedCrossRef

72.

Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115:610–621PubMed

73.

Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238PubMedCrossRef

74.

Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543PubMedCrossRef

75.

Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 15:3073–3082PubMedCrossRef

76.

Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH (2010) Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 16:49–54PubMedCrossRef

77.

Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M (2009) Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 12:7–14PubMedCrossRef

78.

Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2008) Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 10:997–1000PubMedCrossRef

79.

Vaidya VS, Ferguson MA, Bonventre JV (2008) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463–493PubMedCrossRef

80.

Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL (2006) Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 70:199–203PubMedCrossRef

81.

Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73:213–224PubMedCrossRef

82.

Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, Seidler T, Hasenfuss G, Chvatchko Y, Shah AM, Tedgui A (2004) Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 18:1752–1754PubMed

83.

Hartford M, Wiklund O, Hulten LM, Persson A, Karlsson T, Herlitz J, Hulthe J, Caidahl K (2010) Interleukin-18 as a predictor of future events in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 30:2039–2046PubMedCrossRef

84.

Veerkamp JH, Paulussen RJ, Peeters RA, Maatman RG, van Moerkerk HT, van Kuppevelt TH (1990) Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein types. Mol Cell Biochem 98:11–18PubMedCrossRef

85.

Maatman RG, van Kuppevelt TH, and Veerkamp JH (1991) Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J 273(Pt 3):759–766

86.

Noiri E, Doi K, Negishi K, Tanaka T, Hamasaki Y, Fujita T, Portilla D, Sugaya T (2009) Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 296:F669–F679PubMedCrossRef

87.

Ferguson MA, Vaidya VS, Waikar SS, Collings FB, Sunderland KE, Gioules CJ, Bonventre JV (2010) Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 77:708–714PubMedCrossRef

88.

Niizeki T, Takeishi Y, Arimoto T, Nozaki N, Hirono O, Watanabe T, Nitobe J, Miyashita T, Miyamoto T, Koyama Y, Kitahara T, Suzuki S, Sasaki T, Kubota I (2008) Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 72:109–114PubMedCrossRef

Title: Current and novel renal biomarkers in heart failure
Authors: Kevin Damman
Adriaan A. Voors
Gerjan Navis
Dirk J. van Veldhuisen
Hans L. Hillege
Publication date: 01-03-2012
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2012
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-011-9254-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current and novel renal biomarkers in heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Loop diuretics in heart failure

Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure

Can we prevent or treat renal dysfunction in acute heart failure?

Can we prevent or treat renal dysfunction in chronic heart failure?

A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function

Cardio-renal syndromes: a systematic approach for consensus definition and classification

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page